Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
60 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men and women over 60 years old at the time of written consent
Those admitted to the hospital within 72 hours after acute cerebral infarction and treated with Aspirin 100 mg and Clopidogrel 75 mg
Written informed consent voluntarily signed
Those with evidence other brain lesions such as brain tumors
Those who need oral anticoagulants other than vitamin K antagonists or anticoagulant therapy of warfarin
Contraindicate to Aspirin or Clopidogrel or allergic to the drug
Subjects who are at risk of active pathological bleeding such as digestive ulcer and intracranial hemorrhage
Cancer disease that can shorten life expectancy
Patient's condition that may interfere with participation in study such as mental illness, mental retardation, dementia, drug abuse, and alcoholism
Subjects other than the above unsuitable for this clinical study identified by Investigator